Scientists probe why Anti-B cell therapies fail in kidney rejection
NCT ID NCT07134491
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at why some kidney transplant rejections don't respond to treatments that target B cells. Researchers will collect blood, stool, and kidney tissue from 45 patients to study B cell behavior and antibody reactions. The goal is to uncover the hidden triggers of rejection and find clues for better therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal why some kidney transplant rejections resist current treatments, pointing toward new therapies.
- What could go wrong
- This is an early-stage observational study with only 45 participants. It aims to understand mechanisms, not test a treatment, so direct patient benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nephrology department, Hôpital Pitié Salpêtière
RECRUITINGParis, 75013, France
-
Nephrology department, Tenon hospital
NOT_YET_RECRUITINGParis, 75020, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.